Amneal Pharmaceuticals’ (AMRX) “Overweight” Rating Reiterated at Piper Sandler

Piper Sandler restated their overweight rating on shares of Amneal Pharmaceuticals (NASDAQ:AMRX) in a research note released on Friday morning,Benzinga reports. The brokerage currently has a $13.00 price objective on the stock, up from their prior price objective of $11.00.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upped their target price on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.50.

Amneal Pharmaceuticals Trading Up 8.1%

Shares of AMRX stock opened at $10.81 on Friday. The business’s fifty day simple moving average is $9.95 and its 200-day simple moving average is $8.66. The company has a market cap of $3.40 billion, a PE ratio of 1,082.08 and a beta of 1.18. Amneal Pharmaceuticals has a 12-month low of $6.68 and a 12-month high of $10.97.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.03. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, equities analysts forecast that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 22,000 shares of Amneal Pharmaceuticals stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $199,100.00. Following the completion of the transaction, the executive vice president owned 10,606 shares in the company, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Nikita Shah sold 114,492 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $9.66, for a total value of $1,105,992.72. Following the transaction, the executive vice president owned 152,743 shares of the company’s stock, valued at $1,475,497.38. The trade was a 42.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 609,206 shares of company stock valued at $5,700,625 in the last quarter. Insiders own 26.56% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of institutional investors have recently modified their holdings of AMRX. Headlands Technologies LLC purchased a new position in shares of Amneal Pharmaceuticals during the 1st quarter valued at about $31,000. Exchange Traded Concepts LLC purchased a new position in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $31,000. Amalgamated Bank raised its stake in shares of Amneal Pharmaceuticals by 33.0% during the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company’s stock valued at $46,000 after buying an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. raised its stake in shares of Amneal Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 7,934 shares of the company’s stock valued at $66,000 after buying an additional 1,428 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Amneal Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company’s stock valued at $98,000 after buying an additional 1,735 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.